One-time gene therapy aims to restore hearing in kids with genetic deafness
Disease control
Recruiting now
This early-stage trial tests a new gene therapy called SKY-GJB2 for children aged 9 months to 7 years with hearing loss caused by changes in the GJB2 gene. The therapy is given as a single injection into the inner ear using a special delivery device. The study will enroll 10 chil…
Phase: PHASE1, PHASE2 • Sponsor: Skylark Bio Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC